Long‐term weight control study V (weeks 190 to 210): Follow‐up of participants after cessation of medication

Michael Weintraub, Pavur R. Sundaresan, Barbara Schuster, Mordechai Averbuch, E. Carol Stein, Louise Byrne

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Participants who completed up to week 190 in the long‐term weight control study were monitored after cessation of medication between weeks 190 and 210. Caloric restriction, behavior modification sessions, exercise reinforcement, and physician visits continued. We assessed whether or not participants had reset their weight control mechanisms and compared the effect of stopping medication under open‐label conditions (weeks 190 to 210) with the results of stopping anorexiants under double‐blind conditions (weeks 160 to 190). At week 210, participants were, on average, 1.4 ± 1.0 kg (mean ± SEM, 1.5% ± 1.1%) below their weights at baseline (week 0). Of the 48 participants who remained in the study, 13 were still 5% or more and seven were 10% or more below their initial weights. On average, participants gained 2.7 ± 0.5 kg (3.2%) in the period from weeks 190 to 210. Those who had been taking medication in the period from weeks 160 to 190 gained weight at a somewhat faster rate than those who had been taking placebo. However, participants who had transferred from fenfluramine plus phentermine to no medication in this phase gained at a slower rate than participants who had changed from fenfluramine plus phentermine to placebo under double‐blind conditions at week 160 (0.195 kg per week versus 0.277 kg per week). The findings indicate that participants had difficulty maintaining weight loss without anorexiant medications. Despite long periods of time at weights much lower than baseline, permanent resetting of weight control mechanisms could not be shown for most participants. Clinical Pharmacology and Therapeutics (1992) 51, 615–618; doi:

Original languageEnglish (US)
Pages (from-to)615-618
Number of pages4
JournalClinical Pharmacology & Therapeutics
Volume51
Issue number5
DOIs
StatePublished - Jan 1 1992

Fingerprint

Weights and Measures
Phentermine
Fenfluramine
Placebos
Caloric Restriction
Behavior Therapy
Clinical Pharmacology
Weight Loss
Exercise
Physicians
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Long‐term weight control study V (weeks 190 to 210) : Follow‐up of participants after cessation of medication. / Weintraub, Michael; Sundaresan, Pavur R.; Schuster, Barbara; Averbuch, Mordechai; Stein, E. Carol; Byrne, Louise.

In: Clinical Pharmacology & Therapeutics, Vol. 51, No. 5, 01.01.1992, p. 615-618.

Research output: Contribution to journalArticle

Weintraub, Michael ; Sundaresan, Pavur R. ; Schuster, Barbara ; Averbuch, Mordechai ; Stein, E. Carol ; Byrne, Louise. / Long‐term weight control study V (weeks 190 to 210) : Follow‐up of participants after cessation of medication. In: Clinical Pharmacology & Therapeutics. 1992 ; Vol. 51, No. 5. pp. 615-618.
@article{b3e92f26096b4f80bcf6b53b54291a41,
title = "Long‐term weight control study V (weeks 190 to 210): Follow‐up of participants after cessation of medication",
abstract = "Participants who completed up to week 190 in the long‐term weight control study were monitored after cessation of medication between weeks 190 and 210. Caloric restriction, behavior modification sessions, exercise reinforcement, and physician visits continued. We assessed whether or not participants had reset their weight control mechanisms and compared the effect of stopping medication under open‐label conditions (weeks 190 to 210) with the results of stopping anorexiants under double‐blind conditions (weeks 160 to 190). At week 210, participants were, on average, 1.4 ± 1.0 kg (mean ± SEM, 1.5{\%} ± 1.1{\%}) below their weights at baseline (week 0). Of the 48 participants who remained in the study, 13 were still 5{\%} or more and seven were 10{\%} or more below their initial weights. On average, participants gained 2.7 ± 0.5 kg (3.2{\%}) in the period from weeks 190 to 210. Those who had been taking medication in the period from weeks 160 to 190 gained weight at a somewhat faster rate than those who had been taking placebo. However, participants who had transferred from fenfluramine plus phentermine to no medication in this phase gained at a slower rate than participants who had changed from fenfluramine plus phentermine to placebo under double‐blind conditions at week 160 (0.195 kg per week versus 0.277 kg per week). The findings indicate that participants had difficulty maintaining weight loss without anorexiant medications. Despite long periods of time at weights much lower than baseline, permanent resetting of weight control mechanisms could not be shown for most participants. Clinical Pharmacology and Therapeutics (1992) 51, 615–618; doi:",
author = "Michael Weintraub and Sundaresan, {Pavur R.} and Barbara Schuster and Mordechai Averbuch and Stein, {E. Carol} and Louise Byrne",
year = "1992",
month = "1",
day = "1",
doi = "10.1038/clpt.1992.73",
language = "English (US)",
volume = "51",
pages = "615--618",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Long‐term weight control study V (weeks 190 to 210)

T2 - Follow‐up of participants after cessation of medication

AU - Weintraub, Michael

AU - Sundaresan, Pavur R.

AU - Schuster, Barbara

AU - Averbuch, Mordechai

AU - Stein, E. Carol

AU - Byrne, Louise

PY - 1992/1/1

Y1 - 1992/1/1

N2 - Participants who completed up to week 190 in the long‐term weight control study were monitored after cessation of medication between weeks 190 and 210. Caloric restriction, behavior modification sessions, exercise reinforcement, and physician visits continued. We assessed whether or not participants had reset their weight control mechanisms and compared the effect of stopping medication under open‐label conditions (weeks 190 to 210) with the results of stopping anorexiants under double‐blind conditions (weeks 160 to 190). At week 210, participants were, on average, 1.4 ± 1.0 kg (mean ± SEM, 1.5% ± 1.1%) below their weights at baseline (week 0). Of the 48 participants who remained in the study, 13 were still 5% or more and seven were 10% or more below their initial weights. On average, participants gained 2.7 ± 0.5 kg (3.2%) in the period from weeks 190 to 210. Those who had been taking medication in the period from weeks 160 to 190 gained weight at a somewhat faster rate than those who had been taking placebo. However, participants who had transferred from fenfluramine plus phentermine to no medication in this phase gained at a slower rate than participants who had changed from fenfluramine plus phentermine to placebo under double‐blind conditions at week 160 (0.195 kg per week versus 0.277 kg per week). The findings indicate that participants had difficulty maintaining weight loss without anorexiant medications. Despite long periods of time at weights much lower than baseline, permanent resetting of weight control mechanisms could not be shown for most participants. Clinical Pharmacology and Therapeutics (1992) 51, 615–618; doi:

AB - Participants who completed up to week 190 in the long‐term weight control study were monitored after cessation of medication between weeks 190 and 210. Caloric restriction, behavior modification sessions, exercise reinforcement, and physician visits continued. We assessed whether or not participants had reset their weight control mechanisms and compared the effect of stopping medication under open‐label conditions (weeks 190 to 210) with the results of stopping anorexiants under double‐blind conditions (weeks 160 to 190). At week 210, participants were, on average, 1.4 ± 1.0 kg (mean ± SEM, 1.5% ± 1.1%) below their weights at baseline (week 0). Of the 48 participants who remained in the study, 13 were still 5% or more and seven were 10% or more below their initial weights. On average, participants gained 2.7 ± 0.5 kg (3.2%) in the period from weeks 190 to 210. Those who had been taking medication in the period from weeks 160 to 190 gained weight at a somewhat faster rate than those who had been taking placebo. However, participants who had transferred from fenfluramine plus phentermine to no medication in this phase gained at a slower rate than participants who had changed from fenfluramine plus phentermine to placebo under double‐blind conditions at week 160 (0.195 kg per week versus 0.277 kg per week). The findings indicate that participants had difficulty maintaining weight loss without anorexiant medications. Despite long periods of time at weights much lower than baseline, permanent resetting of weight control mechanisms could not be shown for most participants. Clinical Pharmacology and Therapeutics (1992) 51, 615–618; doi:

UR - http://www.scopus.com/inward/record.url?scp=0026589037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026589037&partnerID=8YFLogxK

U2 - 10.1038/clpt.1992.73

DO - 10.1038/clpt.1992.73

M3 - Article

C2 - 1587076

AN - SCOPUS:0026589037

VL - 51

SP - 615

EP - 618

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -